

References

L-189

1. DiMauro S, Hirano M. MELAS. 2001 Feb 27 [Updated 2013 Nov 21]. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2016.
2. K. Majamaa, J.S. Moilanen, S. Uimonen, A.M. Remes, P.I. Salmela, M. Kärppä, K.A.Majamaa-Voltti, H. Rusanen, M. Sorri, K.J. Peuhkurinen, I.E. Hassinen, Epidemiology of A3243G, the mutation for mitochondrial encephalomyopathy, lactic acidosis, and stroke like episodes: prevalence of the mutation in an adult population. *Am. J. Hum.Genet.* 1998;63:447–454.
3. J. Uusimaa, J.S. Moilanen, L. Vainionpää, P. Tapanainen, P. Lindholm, M. Nuutinen, T.Löppönen, E. Mäki-Torkko, H. Rantala, K. Majamaa, Prevalence, segregation, and phenotype of the mitochondrial DNA 3243ANG mutation in children. *Ann. Neurol.* 2007;62:278–287.
4. Parikh S, Goldstein A, Koenig MK, Scaglia F, Enns G, Saneto R, Anselm I, Cohen B, Falk M, Greene C, Gropman A, Haas R, Hirano M, Morgan P, Sims K, Tanopolsky M, Van Hove JLK, Wolfe L, DiMauro S. Diagnosis and management of mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society. *Gen in Med.* 2015;17:689-701.
5. Y. Koga, Y. Akita, J. Nishioka, S. Yatsuga, N. Povalko, Y. Tanabe, S. Fujimoto, T.Matsuishi, L-Arginine improves the symptoms of stroke-like episodes in MELAS. *Neurology.* 2005;64:710–712.
6. Y. Koga, Y. Akita, J. Nishioka, S. Yatsuga, N. Povalko, K. Katayama, T. Matsuishi, MELAS and L-arginine therapy. *Mitochondrion* 2007;7:133–139.
7. A.W. El-Hattab, J.W. Hsu, L.T. Emrick, L.J. Wong, W.J. Craigen, F. Jahoor, F. Scaglia, Restoration of impaired nitric oxide production in MELAS syndrome with citrulline and arginine supplementation. *Mol. Genet. Metab.* 2012;105:607–614.
8. A.W. El-Hattab, L.T. Emrick, W.J. Craigen, F. Scaglia, Citrulline and arginine utility in treating nitric oxide deficiency in mitochondrial disorders. *Mol. Genet. Metab.* 2012;107:247–252.
9. K. Majamaa, J.S. Moilanen, S. Uimonen, A.M. Remes, P.I. Salmela, M. Kärppä, K.A.Majamaa-Voltti, H. Rusanen, M. Sorri, K.J. Peuhkurinen, I.E. Hassinen, Epidemiology of A3243G, the mutation for mitochondrial encephalomyopathy, lactic acidosis, and stroke like episodes: prevalence of the mutation in an adult population. *Am. J. Hum.Genet.* 1998;63:447–454.
10. Mao C, Holt I. Clinical and Molecular Aspects of Diseases of Mitochondrial DNA Instability. *Chang Gung Med J.* 2009;32:354-69.
11. Clinical Molecular Genetics Society Guidelines (CMGS), UK. Practice guidelines for the molecular diagnosis of mitochondrial diseases. July 2008. www.acgs.uk.com/media/774654/mito_2008.pdf
12. Finsterer J, Harbo HF, Baets J, et al.; European Federation of Neurological Sciences. EFNS guidelines on the molecular diagnosis of mitochondrial disorders. *Eur J Neurol.* 2009;16(12):1255-64.
13. National Institute of Neurological Disorders and Stroke (NINDS, NIH). www.ninds.nih.gov/news_and_events/proceedings/20090629_mitochondrial.htm.